Evidence map›Paper›PMID 40787455›Full record

ArticleFrontiers in immunology2025

The effectiveness and safety of ofatumumab for the treatment of pemphigus vulgaris: a cohort study based on a registry database.

Xiwen Zhang, Yiyi Wang, Ping Tan, Xingli Zhou, Yue Xiao, Xun Feng, Jishu Li, Mintong Wei, Min Zou, Gyeongah Kim and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Xiwen Zhang *Department of Dermatology & Rare Disease Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yiyi Wang *Department of Dermatology & Rare Disease Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Ping Tan *Department of Dermatology & Rare Disease Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Xingli ZhouDepartment of Dermatology & Rare Disease Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yue XiaoDepartment of Dermatology & Rare Disease Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Xun FengDepartment of Dermatology & Rare Disease Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Jishu LiDepartment of Dermatology & Rare Disease Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Mintong WeiDepartment of Dermatology & Rare Disease Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Min ZouDepartment of Dermatology & Rare Disease Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Gyeongah KimDepartment of Dermatology & Rare Disease Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Lu JiangDepartment of Dermatology & Rare Disease Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Xiaohong LiDepartment of Dermatology & Rare Disease Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Jinqiu WangDepartment of Outpatient, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Mi WangDepartment of Dermatology & Rare Disease Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Wei LiDepartment of Dermatology & Rare Disease Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ofatumumab, a fully human anti-CD20 monoclonal antibody administered subcutaneously and indicated for multiple sclerosis, might theoretically be effective for patients with pemphigus vulgaris (PV). Objective: To evaluate the effectiveness and safety of ofatumumab in patients with PV. Methods: This cohort study was based on a registry database of autoimmune bullous diseases at West China Hospital (AIBD-WCH), including two groups. One was ofatumumab (OFA) group, involving patients receiving ofatumumab subcutaneous injections (2×20mg, 2 weeks apart) and systemic glucocorticoids with/without immunosuppressant. The glucocorticoids control (GC) group was matched using propensity score matching in a 1:2 ratio based on sex, age and body mass index. Both groups completed regular follow-up for 52 weeks. The primary endpoint was the proportion of patients achieving complete remission during therapy (CRDT) at week 52. Secondary endpoints included maintaining treatment (MT) with daily prednisone doses <0.2 mg/kg/d, relapse rate, the change of pemphigus disease area index and cumulative glucocorticoid doses. Safety results were also collected. Results: Sixteen and thirty-two patients were included in OFA and GC groups, respectively. At week 52, more patients in OFA group achieved CRDT (31.2% versus 3.12%, Conclusions: Ofatumumab combined with glucocorticoids demonstrated favorable effectiveness compared with GC group, without increasing severe adverse events.

Indexed as

Antibodies, Monoclonal, HumanizedPemphigusAdultAgedCohort StudiesDatabases, FactualFemaleGlucocorticoidsHumansImmunosuppressive AgentsMaleMiddle AgedRegistriesTreatment OutcomeAntibodies, Monoclonal, HumanizedGlucocorticoidsImmunosuppressive AgentsofatumumabB cell depletionbiologicsCD20 monoclonal antibodyofatumumabpemphigustherapy

Identifiers

PMID40787455
PMCPMC12331720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.